180631-81-6

Basic information

• Product Name: Benzenesulfonamide, N-(4-methoxyphenyl)-3-nitro-
• CAS NO: 180631-81-6
• Molecular Formula: C13H12N2O5S
• Molecular Weight: 308.315
• Mol File: 180631-81-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, N-(4-methoxyphenyl)-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, N-(4-methoxyphenyl)-3-nitro-(180631-81-6)
• EPA Substance Registry System: Benzenesulfonamide, N-(4-methoxyphenyl)-3-nitro-(180631-81-6)

Safety Data

• Hazardous Substances Data: 180631-81-6(Hazardous Substances Data)

Upstream product

• 848652-91-5 N,N-bis-(4-methoxyphenyl)-3-nitrobenzenesulfonamide 
• 104-94-9 4-methoxy-aniline 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Downstream Products

• 201996-24-9 3-amino-N-(4-methoxy-phenyl)-benzenesulfonamide 
• 96-96-8 4-methoxy-2-nitroaniline 
• 860734-45-8 4-methoxy-2,3,6-trinitro-aniline 
• 861549-90-8 4-methoxy-2,5-dinitro-aniline 
• 861602-64-4 3-nitro-benzenesulfonic acid-(4-methoxy-2,5-dinitro-anilide) 
• 861529-91-1 3-nitro-benzenesulfonic acid-(4-methoxy-2,6-dinitro-anilide) 
• 861602-71-3 3-nitro-benzenesulfonic acid-(4-methoxy-2-nitro-anilide) 

Relevant articles and documents

Benzsulfamide IDO1 inhibitor, and preparation method and application thereof

The invention belongs to the field of drugs, and particularly relates to a benzsulfamide compound having a structural characteristic as shown in formula (I) or pharmaceutically acceptable salt of the benzsulfamide compound, a preparation method of the benzsulfamide compound or the salt, and uses of the benzsulfamide compound or the salt as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. An experimental result indicates that the compound provided by the invention has an obvious inhibiting effect on the activity of the IDO1, can effectively promote T cell proliferation, inhibits native T cells from differentiating into regulatory T cells, reverses immunosuppression mediated by the IDO1, and can be used for treating relevant diseases having pathological characteristics of metabolic pathways of kynurenine mediated by the IDO1, including cancer, virus infection, neurodegenerative diseases, cataract, organ transplant rejection, depression, autoimmune diseases and the like. Formula (I) is shown in the description.